Guaifensin Extended-release Tablets, 1200 Mg
NDC Package 62207-698-71

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Guaifensin Extended-release Tablets, 1200 Mg is a . Marketed by Granules India Ltd, this product is identified by NDC 62207-698 and is authorized under FDA application ANDA213420.

Identification & Billing

NDC Package Code
62207-698-71
Package Description
7 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK
Product Code
62207-698
11-Digit Billing Format
62207069871

Clinical Specifications

Proprietary Name
Guaifensin Extended-release Tablets, 1200 Mg
Dosage Form
-

Regulatory & Marketing

Labeler Name
Granules India Ltd
FDA Application #
ANDA213420
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-10-2020
End Marketing Date
06-30-2021
Listing Expiration
06-30-2021
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 62207-698-71 identifies a specific commercial package of 7 blister pack in 1 carton / 10 tablet in 1 blister pack of Guaifensin Extended-release Tablets, 1200 Mg, labeled by Granules India Ltd. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Granules India Ltd on September 10, 2020. The current certification is valid through June 30, 2021.

How is this Granules India Ltd product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 62207069871. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
62207-698-71
11-Digit CMS (5-4-2)
62207-0698-71

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.